Repligen Co. (NASDAQ:RGEN) Director Acquires $37,672.50 in Stock

Repligen Co. (NASDAQ:RGEN) Director Margaret Pax bought 250 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was bought at an average cost of $150.69 per share, with a total value of $37,672.50. Following the transaction, the director now directly owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Repligen Price Performance

Shares of RGEN traded down $8.47 during trading hours on Tuesday, hitting $144.34. 1,156,151 shares of the company were exchanged, compared to its average volume of 646,141. The company has a market capitalization of $8.09 billion, a PE ratio of -283.02, a PEG ratio of 4.54 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The firm has a fifty day simple moving average of $157.16 and a 200-day simple moving average of $148.53. Repligen Co. has a one year low of $113.50 and a one year high of $200.23.

Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. The company had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. As a group, sell-side analysts predict that Repligen Co. will post 1.72 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently commented on RGEN shares. JPMorgan Chase & Co. boosted their price target on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. StockNews.com cut Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. Canaccord Genuity Group boosted their price target on Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research note on Friday, February 21st. Royal Bank of Canada upped their price objective on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research note on Friday, February 21st. Finally, HC Wainwright restated a “buy” rating and set a $180.00 price objective on shares of Repligen in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Repligen currently has an average rating of “Hold” and an average price target of $178.64.

Institutional Trading of Repligen

Hedge funds have recently modified their holdings of the business. Signaturefd LLC raised its holdings in shares of Repligen by 172.2% during the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 124 shares in the last quarter. Sava Infond d.o.o. acquired a new position in Repligen during the fourth quarter worth $29,000. Raiffeisen Bank International AG acquired a new position in Repligen during the fourth quarter worth $29,000. Resources Management Corp CT ADV acquired a new position in Repligen during the third quarter worth $37,000. Finally, Quarry LP increased its position in Repligen by 796.7% during the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after buying an additional 239 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.